Table 6 Treatment-related toxicities after each cycle of topotecan and cyclophosphamide containing induction therapy
|  | Data | First cycle | Second cycle |
|---|---|---|---|
Hospital stay (days) | Median (range) | 7 (5–10) | 5 (5–40) |
Nadir period (days) | Median (range) | 15 (10–20) | 15 (10–20) |
Readmission after chemotherapy | No | 71 (66.4) | 88 (82.2) |
Ward | 33 (30.8) | 18 (16.8) | |
ICU | 3 (2.8) | 1 (0.9) | |
Febrile neutropenia | No | 63 (58.9) | 86 (80.4) |
Yes | 44 (41.1) | 21 (19.6) | |
Mucositis | No | 84 (78.5) | 93 (86.9) |
Yes | 23 (21.5) | 14 (13.1) | |
Diarrhea | No | 102 (95.3) | 103 (96.3) |
Yes | 5 (4.7) | 4 (3.7) | |
Typhlitis | No | 106 (99.1) | 106 (99.1) |
Yes | 1 (0.9) | 1 (0.9) | |
Renal dysfunction | No | 106 (99.1) | 106 (99.1) |
Yes | 1 (0.9) | 1 (0.9) | |
Elevated liver enzymes | No | 105 (98.1) | 106 (99.1) |
Yes | 2 (1.9) | 1 (0.9) |